{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30","value":"262"}]}],"title":"Cmax at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65","value":"28.3"}]}],"title":"Cmin at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38","value":"237"}]}],"title":"Cmax at Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63","value":"38.4"}]}],"title":"Cmin at Cycle 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"594"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"On Day 1 of each 21-day cycle, participants received ramucirumab DP followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Ramucirumab DP: 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG000","title":"Ramucirumab and Docetaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants assigned to the ramucirumab and docetaxel arm at randomization, who had evaluable ramucirumab pharmacokinetic (PK) data to calculate Cmax and Cmin.","reportingStatus":"POSTED","timeFrame":"Prior to infusion and 1 hour following infusion for 4 and 8 (cycles 3 and 5 at 21 days/cycle)","title":"Maximum and Minimum Serum Concentrations (Cmax and Cmin) of Ramucirumab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter (mcg/mL)"}